[go: up one dir, main page]

WO2003031572A3 - Polypeptides therapeutiques, acides nucleiques codant ces derniers et methodes d'utilisation - Google Patents

Polypeptides therapeutiques, acides nucleiques codant ces derniers et methodes d'utilisation Download PDF

Info

Publication number
WO2003031572A3
WO2003031572A3 PCT/US2002/031359 US0231359W WO03031572A3 WO 2003031572 A3 WO2003031572 A3 WO 2003031572A3 US 0231359 W US0231359 W US 0231359W WO 03031572 A3 WO03031572 A3 WO 03031572A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
nucleic acids
acids encoding
encoding same
therapeutic polypeptides
Prior art date
Application number
PCT/US2002/031359
Other languages
English (en)
Other versions
WO2003031572A2 (fr
Inventor
John P. Ii Alsobrook
Catherine E. Burgess
Linda Gorman
Xiaojia Guo
Denise M. Lepley
Meera Patturajan
Luca Rastelli
Daniel K. Rieger
Kimberly A. Spytek
Mei Zhong
Original Assignee
Curagen Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Curagen Corporation filed Critical Curagen Corporation
Priority to AU2002356534A priority Critical patent/AU2002356534A1/en
Publication of WO2003031572A2 publication Critical patent/WO2003031572A2/fr
Publication of WO2003031572A3 publication Critical patent/WO2003031572A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne de nouveaux polypeptides, et les acides nucléiques codant ces derniers, présentant des propriétés associées à la stimulation de réponses biochimiques ou physiologiques dans une cellule, un tissu, un organe ou un organisme. Plus particulièrement, lesdits nouveaux polypeptides sont des produits génétiques de gènes nouveaux, ou leurs fragments ou dérivés spécifiques biologiquement actifs. Les méthodes d'utilisation comprennent des méthodes d'analyse diagnostique et pronostique ainsi que des méthodes de traitement de divers états pathologiques.
PCT/US2002/031359 2001-10-09 2002-10-02 Polypeptides therapeutiques, acides nucleiques codant ces derniers et methodes d'utilisation WO2003031572A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002356534A AU2002356534A1 (en) 2001-10-09 2002-10-02 Therapeutic polypeptides, nucleic acids encoding same, and methods of use

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
US32802901P 2001-10-09 2001-10-09
US32791701P 2001-10-09 2001-10-09
US32805601P 2001-10-09 2001-10-09
US60/328,056 2001-10-09
US60/327,917 2001-10-09
US60/328,029 2001-10-09
US34957501P 2001-10-29 2001-10-29
US60/349,575 2001-10-29
US38103802P 2002-05-16 2002-05-16
US60/381,038 2002-05-16
US10/262,473 2002-10-01
US10/262,473 US20030199442A1 (en) 2001-10-09 2002-10-01 Therapeutic polypeptides, nucleic acids encoding same, and methods of use

Publications (2)

Publication Number Publication Date
WO2003031572A2 WO2003031572A2 (fr) 2003-04-17
WO2003031572A3 true WO2003031572A3 (fr) 2010-05-27

Family

ID=29220076

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/031359 WO2003031572A2 (fr) 2001-10-09 2002-10-02 Polypeptides therapeutiques, acides nucleiques codant ces derniers et methodes d'utilisation

Country Status (3)

Country Link
US (1) US20030199442A1 (fr)
AU (1) AU2002356534A1 (fr)
WO (1) WO2003031572A2 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10254214A1 (de) * 2002-11-20 2004-06-09 Beiersdorf Ag Oligoribonukleotide zur Behandlung von degenerativen Hauterscheinungen durch RNA-Interferenz
US7763256B2 (en) 2002-12-23 2010-07-27 William Marsh Rice University Compositions and methods for suppressing fibrocytes and for detecting fibrocyte differentiation
ES2318195T3 (es) 2002-12-23 2009-05-01 William Marsh Rice University Metodos y composiciones para potenciar la formacion de fibrocitos.
US8012472B2 (en) 2002-12-23 2011-09-06 William Marsh Rice University Compositions and methods for suppressing fibrocytes
US20050244839A1 (en) * 2004-04-29 2005-11-03 Cheung Siu T Granulin-epithelin precursor (GEP) overexpression as a target for diagnosis, prognosis and treatment of hepatocellular carcinoma (HCC)
EP2094289B1 (fr) 2006-12-04 2013-03-13 Promedior, Inc. Combinaison de sap et de l'énalapril pour utilisation dans le traitement des maladies fibrotique ou fibroprolifératifs
US9884899B2 (en) 2007-07-06 2018-02-06 Promedior, Inc. Methods for treating fibrosis using CRP antagonists
US8497243B2 (en) 2007-07-06 2013-07-30 Promedior, Inc. Methods and compositions useful in the treatment of mucositis
JP2012505644A (ja) * 2008-10-15 2012-03-08 エフ．ホフマン−ラ ロシュ アーゲー オリゴヌクレオチド検出法
EP2405929B1 (fr) 2009-03-11 2018-06-06 Promedior Inc. Un sap polypeptide et son utilisation dans le traitement de troubles auto-immuns et de la reaction du gréffon contre l'hôte.
WO2010104959A1 (fr) 2009-03-11 2010-09-16 Promedior, Inc. Procédés de traitement et de diagnostic pour troubles d'hypersensibilité
UA110323C2 (en) 2009-06-04 2015-12-25 Promedior Inc Derivative of serum amyloid p and their receipt and application
EP2443144B1 (fr) 2009-06-17 2015-08-19 Promedior, Inc. Variants de la sap et leur utilisation

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) * 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4873191A (en) * 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
US4485045A (en) * 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4522811A (en) * 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4870009A (en) * 1982-11-22 1989-09-26 The Salk Institute For Biological Studies Method of obtaining gene product through the generation of transgenic animals
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) * 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4736866B1 (en) * 1984-06-22 1988-04-12 Transgenic non-human mammals
US4683202A (en) * 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4676980A (en) * 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5225539A (en) * 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4987071A (en) * 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US5116742A (en) * 1986-12-03 1992-05-26 University Patents, Inc. RNA ribozyme restriction endoribonucleases and methods
US4873316A (en) * 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US5080891A (en) * 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) * 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5272057A (en) * 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5328470A (en) * 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US5459039A (en) * 1989-05-12 1995-10-17 Duke University Methods for mapping genetic mutations
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
DK0463151T3 (da) * 1990-01-12 1996-07-01 Cell Genesys Inc Frembringelse af xenogene antistoffer
US5545806A (en) * 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) * 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
KR100272077B1 (ko) * 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
US5625126A (en) * 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) * 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5969097A (en) * 1992-06-23 1999-10-19 G. D. Searle & Co. Human guanylin
EP0657811B1 (fr) * 1993-12-09 1998-09-02 STMicroelectronics S.r.l. Circuit intégré de contrÔle de l'utilisation des éléments de mémoire redondantes dans un dispositif de mémoire à semi-conducteurs
US6083693A (en) * 1996-06-14 2000-07-04 Curagen Corporation Identification and comparison of protein-protein interactions that occur in populations
US5916771A (en) * 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MANTZOURANIS, E.C. ET AL.: "Human Serum Amyloid P Component", vol. 260, June 1985 (1985-06-01), pages 7752 - 7756 *
PEPYS, M.B. ET AL.: "Human serum amyloid P component is an invariant constituent of amyloid deposits and has a uniquely homogeneous glycostructure.", vol. 91, June 1994 (1994-06-01), pages 5602 - 5606 *

Also Published As

Publication number Publication date
AU2002356534A8 (en) 2010-06-24
US20030199442A1 (en) 2003-10-23
WO2003031572A2 (fr) 2003-04-17
AU2002356534A1 (en) 2003-04-22

Similar Documents

Publication Publication Date Title
WO2003031572A3 (fr) Polypeptides therapeutiques, acides nucleiques codant ces derniers et methodes d'utilisation
HUP0004728A1 (hu) Javított eljárás nukleinsav bevitelére többsejtes eukarióta szervezet sejtjeibe és kombinált alkalmazása
EP2280030A3 (fr) Acides nucléiques et protéines correspondantes utiles dans la détection et le traitement des différents cancers
WO1998019167A3 (fr) Gene de classe i du complexe majeur d'histocompatibilite humain a stress cellulaire regule
ATE209684T1 (de) Dna-sequenzen für matrix-metallproteasen, ihre herstellung und verwendung
WO2003076578A3 (fr) Polypeptides therapeutiques, acides nucleiques codant pour eux et leur procede d'utilisation
SG121733A1 (en) Nucleic acid molecules polypeptides and uses therefor, including diagnosis and treatment of alzheimer's disease
WO2001071357A3 (fr) Proteines, genes et leur utilisation pour diagnostiquer et traiter le cancer de la poitrine
WO2002040672A3 (fr) Compositions et methodes relatives a des genes et des proteines specifiques aux seins
WO2001066594A3 (fr) Nouvelles proteines kinases humaines et enzymes analogues de proteines kinases
EP1277843A3 (fr) Nouveaux gènes humains et leurs produits d'expression liés au cancer du colon
WO2004013313A3 (fr) Acides nucleiques antisens
WO2003068921A3 (fr) Polypeptides therapeutiques, acides nucleiques codants pour ceux-ci et techniques d'utilisation
WO2001077338A3 (fr) Nouvelles proteine kinases humaines et nouvelles enzymes de type proteine kinase
WO2001049879A3 (fr) Expression genique et etats biologiques
WO2005014804A3 (fr) Protease specifique a l'ubiquitine
WO2000058464A3 (fr) Genes rab et leurs utilisations
WO2005023979A3 (fr) Molecules d'acide nucleique de s. mansoni isolees et utilisations associees
CY1110911T1 (el) Ανθρωπινο γονιδιο tsc403
EP1494031A3 (fr) Nouveaux gènes humains et leurs produits d'expression
EP1293570A3 (fr) Utilisation du gène de l'aprataxine pour le diagnostic et le traitement de l'ataxie spino-cérébelleuse à apparition précoce (EAOH)
WO2005049818A3 (fr) Gene
WO2001092524A3 (fr) Gene du type myosine exprime dans le coeur et les muscles humains
WO2006034007A3 (fr) Procedes permettant de traiter des troubles metaboliqes par la modulation de la serine/threonine kinase 2 inductible par des sels
WO2004090113A3 (fr) L53, antigene associe au cancer du poumon et ses utilisations

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)